Silexion Therapeutics (SLXN) Stock Statistics & Valuation Metrics

Silexion Therapeutics has a market cap or net worth of $1.50M. The enterprise value is $0.90.

Silexion Therapeutics has 5,755,872 shares outstanding. The number of shares has decreased by -2.65% in one year.

Silexion Therapeutics’s return on equity (ROE) is -4.58 and return on invested capital (ROIC) is 250.74%.

The current PE Ratio of Silexion Therapeutics is ―. Silexion Therapeutics’s PEG ratio is 0.00219.

In the last 12 months, Silexion Therapeutics had revenue of 0.00 and earned -11.91M in profits. Earnings per share was -89.60.

In the last 12 months, operating cash flow was -12.43M and capital expenditures -2.00K, giving a free cash flow of -12.43M billion.

Silexion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Silexion Therapeutics upcoming earnings date is Nov 18, 2026, After Close (Confirmed).

Silexion Therapeutics as a current ratio of 2.41, with Debt / Equity ratio of 3204.55%

In the past 12 months, Silexion Therapeutics has paid 3.00K in taxes.

Silexion Therapeutics EV to EBITDA ratio is 0.25, with an EV/FCF ratio of 0.27.

Silexion Therapeutics has $2.23M in cash and marketable securities with $1.41M in debt, giving a net cash position of $819.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Silexion Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold